HD 204

Drug Profile

HD 204

Alternative Names: Bevacizumab biosimilar - Prestige BioPharma/Hanwha Biologics; HD 204; HD 205

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanwha Biologics
  • Developer Hanwha Biologics; Prestige BioPharma
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours
  • Discontinued Autoimmune disorders

Most Recent Events

  • 10 Jan 2018 Prestige Biopharma plans a phase III trial for Non-small Cell Lung Cancer (Metastatic disease, recurrent) in USA in January 2018(NCT03390686)
  • 09 Jan 2018 Prestige Biopharma plans a phase I trial of HD 204 in comparison with Bevacizumab (Avastin) in healthy volunteers in April 2018 (NCT03390673)
  • 08 Aug 2017 Discontinued for Autoimmune disorders in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top